• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

chemotherapy - Articles and news items


Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has […]

pancreatic cancer

Onivyde receives positive CHMP opinion for pancreatic cancer treatment

Industry news / 25 July 2016 / Niamh Louise Marriott, Digital Content Producer

The positive opinion is based on a pivotal Phase 3 study showing that Onivyde combined with chemotherapy significantly increased overall survival in patients with metastatic pancreatic cancer…

Old and New drugs sarcoma cancer

Combining soft-tissue cancer drugs improves survival

Industry news / 21 July 2016 / Niamh Louise Marriott, Digital Content Producer

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with lethal soft-tissue cancer…

Gazyvaro Roche

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +